Roche Pays $190M Upfront for Hanmi’s First-in-Class Obesity Drug — BigGo Finance
Roche has placed a significant bet on a next-generation obesity treatment from South Korea’s Hanmi Pharm, paying $190…
Roche outlays $2.3bn for Hanmi’s non-GLP-1 obesity candidate
Roche has conducted its joint-largest deal of the year so far, licensing a clinical-stage UCN2 (urocortin-2) analog being…